Patient-derived Organoids of Lung Cancer to Test Drug Response
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Geneva
About this trial
This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 3 years. The purpose of this study is to evaluate the consistency and accuracy of a Patient-Derived Organoid (PDO) Model of lung cancer to predict the clinical efficacy of anti-cancer drugs, in order to predict the best chemotherapy regimen for each given patient.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histologically proven lung cancer
Age ≥ 18
Written informed and signed consent
Accessible to biopsy and/or surgery sample of metastasis and/or primitive tumour
Disqualifiers
Less than 18 years of age
Not able to give informed consent (language, intellectual capacities, etc.)
Not accessible to biopsy and/or surgery sample
Not enough lung tissue for a histological analysis or the remaining lung tissue is not enough to perform a routine pathological analysis.
Trial population
All patients (estimated 50 patients) with histologically proven lung cancer undergoing surgery related to this cancer at the University Hospitals of Geneva.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Lung tumor resection
Procedure/Surgerylung tumor resection
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Patient-derived organoid establishment
Successful generation of lung cancer organoids (growth of lung tumoral cells). The rate of successful generation of lung cancer organoids could vary with the age of the patient, the histological and molecular subtype of lung cancer
Time frame
3 years2
Patient-derived organoid validation
Proportion of patient-derived organoids that are histologically and genetically identical to the source tumour
Time frame
5 yearsSecondary outcomes
1
Drug sensitivity
Drug sensitivity of patient-derived tumour organoids (drug screening and chemotherapy resistance test) Secondary drug effects on patient-derived normal lung organoids
Time frame
2019 - 20232
Prediction of the response to treatment by the patient-derived organoids
The drug sensitivity was tested on patient-derived tumour organoids, which is compared with clinical response of the chemo- or targeted therapy treatment.
Time frame
2020 - 2025Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov